Cowen & Co. Reaffirms Their Buy Rating on Esperion (ESPR)


In a report released today, Chris Shibutani from Cowen & Co. maintained a Buy rating on Esperion (ESPR), with a price target of $94. The company’s shares opened today at $42.68.

According to TipRanks.com, Shibutani is a 2-star analyst with an average return of 0.0% and a 40.0% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Lexicon Pharmaceuticals, and Pieris Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Esperion with a $91.83 average price target, an 115.2% upside from current levels. In a report issued on January 4, JMP Securities also reiterated a Buy rating on the stock with a $153 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $82.68 and a one-year low of $33.06. Currently, Esperion has an average volume of 822.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Esperion Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C).

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts